NovaBridge Biosciences (NBP) EBIAT (2019 - 2025)
NovaBridge Biosciences (NBP) posted EBIAT of -$72.9 million for Q4 2025, down 967.05% on a QoQ basis from -$6.8 million in Q3 2025, and down 116.74% YoY from $435.3 million in Q4 2024.
NovaBridge Biosciences (NBP) EBIAT (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported EBIAT for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 116.74% year-over-year to -$72.9 million; the trailing twelve-month figure through Dec 2025 stood at -$88.3 million (down 96.3% YoY), and the FY2025 full-year result was -$88.3 million, down 297.39% from the prior year.
- EBIAT retreated to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $67.9 million in Q4 2023 to a low of -$72.9 million in Q4 2025.
- Median EBIAT over the past 3 years was -$6.8 million (2025), compared with a mean of -$8.5 million.
- Biggest YoY gain for EBIAT was 141.36% in 2024; the steepest drop was 161.62% in 2024.
- A 3-year view of EBIAT shows it stood at $67.9 million in 2023, then tumbled by 149.51% to -$33.6 million in 2024, then plunged by 116.74% to -$72.9 million in 2025.
- Per Business Quant, the three latest NBP EBIAT figures stand at -$72.9 million (Q4 2025), -$6.8 million (Q3 2025), and -$5.5 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | NovaBridge Biosciences | 330.39 Mn | 119.55 Mn | - | -72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -33.62 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | 25.42 Mn |
| Mar 31, 2024 | -16.32 Mn |
| Dec 31, 2023 | 67.90 Mn |
| Sep 30, 2023 | 33.26 Mn |
| Jun 30, 2023 | -61.47 Mn |
| Dec 31, 2020 | -15.05 Mn |
| Sep 30, 2020 | 82.53 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |